ADMA Biologics, Inc. · 3 months ago
Technician I, Fractionation
ADMA Biologics is a biopharmaceutical company committed to creating superior products for immunodeficient patients at risk for infection. They are seeking a Technician I, Fractionation to assist in the manufacturing of plasma products, focusing on cleaning, sanitizing, and preparing equipment and solutions.
BiotechnologyHealth CareManufacturingMedical
Responsibilities
Cleans and Sanitizes Equipment before and after use
Cleans and Sanitizes Manufacturing Areas daily
Operates COP washer
Receives and de-boxes plasma units
Operates plasma bottle cutter
Operates pooling tank lift
Set up and harvest centrifuges
Monitors centrifuge flow and temperatures
Prepares buffer solutions
Removes trash (empty plasma bottles, etc) from the TCP and Fractionation areas
Maintains stock of gowning supplies
Make connections on flow panels for product transfers
Follow manufacturing SOP’s and Batch Records
Additional tasks associated with advancement to the Tech II position
Qualification
Required
High School Diploma or GED
Ability to follow the cGMP's and procedures with great attention to detail
Preferred
Associate degree or equivalent experience preferred
GMP experience preferred
Benefits
401K plan with employer match and immediate vesting
Medical, Vision, Life and Dental Insurance
Pet Insurance
Company paid STD and LTD
Company Paid Holidays
3 Weeks’ Paid Time Off (within the first year)
Tuition Assistance (after the first year)
Easily accessible to Tri-Rail
Free shuttle to the Boca Tri-Rail station
Company
ADMA Biologics, Inc.
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
Funding
Current Stage
Public CompanyTotal Funding
$1.04BKey Investors
JP MorganAres ManagementHayfin Capital Management
2025-08-06Post Ipo Debt· $300M
2023-12-18Post Ipo Debt· $135M
2022-12-07Post Ipo Equity· $60M
Recent News
MarketScreener
2026-01-05
2025-11-07
Company data provided by crunchbase